DOI: 10.6084/m9.figshare.25746990.v1
title: Supplementary materials: Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA

description: <b>These are peer-reviewed supplementary materials for the article '</b><b>Comparative economic outcomes in </b><b>patients with focal seizures initiating </b><b>eslicarbazepine acetate versus </b><b>brivaracetam in the long-term care setting </b><b>in the USA</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Table S1: </b>Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis by ASM cohort<b>Supplementary Table S2: </b>Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by IDD, by ASM cohort<b>Supplementary Table S3: </b>Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by age ≥ 65 years, by ASM cohort<b>Supplementary Table S4: </b>Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by 0–1 prior ASMs, by ASM cohort<b>Supplementary Table S5: </b>Baseline clinical characteristics for patients with any epilepsy or seizure diagnosis by ASM cohort, pre and post-IPTWSupplementary Table S6: Baseline clinical characteristics of patients with any epilepsy or seizure diagnosis stratified by IDD, by ASM cohort<b>Supplementary Table S7: </b>Baseline clinical characteristics for patients with any epilepsy or seizure diagnosis stratified by age ≥ 65 years, by ASM cohort<b>Supplementary Table S8: </b>Baseline clinical characteristics of patients with any epilepsy or seizure diagnosis stratified by 0–1 prior ASMs<b>Supplementary Table S9: </b>All-cause and epilepsy-specific healthcare costs over the post-index period in patients with any epilepsy or seizure diagnosis, by ASM cohort<b>Supplementary Figure S1: </b>Sensitivity analysis: Key inclusion and exclusion criteria for patients with any epilepsy or seizure diagnosis<b>Supplementary Figure S2: </b>Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results post-IPTW)<b>Supplementary Figure S3: </b>Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis with IDD in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)<b>Supplementary Figure S4: </b>Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis among patients aged ≥ 65 years in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)<b>Supplementary Figure S5: </b>Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis among patients with 0–1 prior ASMs (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)<b>Aim:</b> To compare all-cause and epilepsy-specific pharmacy and total costs associated with initiation of eslicarbazepine acetate (ESL) or brivaracetam (BRV) among patients with focal seizures in long-term care (LTC) in theUS. <b>Methods:</b> This retrospective analysis used data from IQVIA’s New DataWarehouse. <b>Results: </b>298 patients initiated ESL and 282 patients initiated BRV. Initiation of ESL versus BRV was associated with 33.3% lower all-cause pharmacy costs, 34.4% lower epilepsy-specific pharmacy costs, 21.3% lower all-cause total costs and 30.9% lower epilepsy-specific total costs (all p &lt; 0.0001). <b>Conclusion: </b>Among patients with focal seizures in LTC in the US, initiation of ESL versus BRV was associated with significant reductions in all-cause and epilepsy-specific pharmacy and total costs compared with initiation of BRV.